These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 1680816)

  • 1. Multifactorial resistance in LS174T human colon carcinoma cells selected with doxorubicin.
    Rabier MJ; Bruno NA; Slate DL
    Int J Cancer; 1991 Oct; 49(4):601-7. PubMed ID: 1680816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms and modulation of multidrug resistance in primary human renal cell carcinoma.
    Mickisch GH; Roehrich K; Koessig J; Forster S; Tschada RK; Alken PM
    J Urol; 1990 Sep; 144(3):755-9. PubMed ID: 1974934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P-glycoprotein and alterations in the glutathione/glutathione-peroxidase cycle underlie doxorubicin resistance in HL-60-R, a subclone of the HL-60 human leukemia cell line.
    Raghu G; Pierre-Jerome M; Dordal MS; Simonian P; Bauer KD; Winter JN
    Int J Cancer; 1993 Mar; 53(5):804-11. PubMed ID: 8095491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined in vitro modulation of adriamycin resistance.
    Meijer C; Mulder NH; Timmer-Bosscha H; Peters WH; de Vries EG
    Int J Cancer; 1991 Oct; 49(4):582-6. PubMed ID: 1680815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of glutathione and glutathione-dependent enzymes in the reversal of adriamycin resistance in colon carcinoma cell lines.
    Lai GM; Moscow JA; Alvarez MG; Fojo AT; Bates SE
    Int J Cancer; 1991 Nov; 49(5):688-95. PubMed ID: 1682279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and characterization of doxorubicin-resistant Lewis lung carcinoma variants.
    Bruno NA; Carver LA; Slate DL
    Cancer Commun; 1990; 2(4):151-8. PubMed ID: 1973357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of the mechanism of resistance to Adriamycin in vivo. Glutathione metabolism, P-glycoprotein expression, and drug transport.
    Lee FY; Sciandra J; Siemann DW
    Biochem Pharmacol; 1989 Nov; 38(21):3697-705. PubMed ID: 2574574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stable differentiation of a human colon adenocarcinoma cell line by sodium butyrate is associated with multidrug resistance.
    Ho SB; Yan PS; Dahiya R; Neuschwander-Tetri BA; Basbaum C; Kim YS
    J Cell Physiol; 1994 Aug; 160(2):213-26. PubMed ID: 7913708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
    Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
    J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line.
    Taylor CW; Dalton WS; Parrish PR; Gleason MC; Bellamy WT; Thompson FH; Roe DJ; Trent JM
    Br J Cancer; 1991 Jun; 63(6):923-9. PubMed ID: 1676902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line.
    Chao CC; Huang YT; Ma CM; Chou WY; Lin-Chao S
    Mol Pharmacol; 1992 Jan; 41(1):69-75. PubMed ID: 1346333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of adriamycin-resistant human breast cancer cells which display overexpression of a novel resistance-related membrane protein.
    Chen YN; Mickley LA; Schwartz AM; Acton EM; Hwang JL; Fojo AT
    J Biol Chem; 1990 Jun; 265(17):10073-80. PubMed ID: 1972154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
    David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
    Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion.
    Hamilton TC; Winker MA; Louie KG; Batist G; Behrens BC; Tsuruo T; Grotzinger KR; McKoy WM; Young RC; Ozols RF
    Biochem Pharmacol; 1985 Jul; 34(14):2583-6. PubMed ID: 4040369
    [No Abstract]   [Full Text] [Related]  

  • 15. Characteristics of the glutathione/glutathione-S-transferase detoxification system in melphalan resistant human prostate cancer cells.
    Ripple M; Mulcahy RT; Wilding G
    J Urol; 1993 Jul; 150(1):209-14. PubMed ID: 8510259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
    Lau DH; Lewis AD; Ehsan MN; Sikic BI
    Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential over-expression of mdr1 genes in multidrug-resistant rat glioblastoma cell lines selected with doxorubicin or vincristine.
    Schott B; Bennis S; Pourquier P; Ries C; Londos-Gagliardi D; Robert J
    Int J Cancer; 1993 Aug; 55(1):115-21. PubMed ID: 8102127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleiotropic-resistant phenotype is a multifactorial phenomenon in human colon carcinoma cell lines.
    Toffoli G; Viel A; Tumiotto L; Biscontin G; Rossi C; Boiocchi M
    Br J Cancer; 1991 Jan; 63(1):51-6. PubMed ID: 1671208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line.
    Baas F; Jongsma AP; Broxterman HJ; Arceci RJ; Housman D; Scheffer GL; Riethorst A; van Groenigen M; Nieuwint AW; Joenje H
    Cancer Res; 1990 Sep; 50(17):5392-8. PubMed ID: 1974823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines.
    Huet S; Schott B; Robert J
    Br J Cancer; 1992 Apr; 65(4):538-44. PubMed ID: 1348623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.